Phaseline

Targets › BCMA

BCMA (Tumor necrosis factor receptor superfamily member 17): drug programs, companies and trials

71 programs from 49 companies in 140 trials: 90 Phase 1, 36 Phase 2, 12 Phase 3, 2 Phase 4; Oncology, Immunology, Hematology; next expected readout Dec 2026.

Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. Promotes B-cell survival and plays a role in the regulation of humoral immunity. Activates NF-kappa-B and JNK. (UniProt, Q02223)

Open in Phaseline: the race on BCMA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Regeneron PharmaceuticalsLinvoseltamab
anti-B-cell maturation antigen x anti-CD3 bispecific antibody
BCMA, GPRC5D, CD3E, TNFRSF17Phase 4Relapsed/Refractory Multiple Myeloma (RRMM); Relapsed and/or Refractory Multiple Myeloma (RRMM); Relapsed Refractory Multiple Myeloma (RRMM); High Risk Smoldering Multiple Myeloma (HR-SMM) …Aug 2027
Turun SongBCMA x CD3 Bispecific Antibody
BCMA x CD3 bispecific T-cell engager (BiTE) that engages B cells and plasma cells expressi
BCMA, CD3EPhase 4Antibody Mediated Rejection After Kidney TransplantationDec 2029
AbbVieABBV-383 (Etentamig)
BCMA-directed bispecific antibody
BCMAPhase 3Multiple Myeloma; Relapsed/Refractory Multiple Myeloma; Immunoglobulin Light Chain (AL) AmyloidosisFeb 2027
RocheCevostamab
BCMA-directed bispecific antibody
BCMAPhase 3Multiple MyelomaFeb 2027
AstraZenecaAZD0120
BCMA/CD19 dual CAR T cell therapy
BCMA, CD19Phase 3Relapsed Refractory Multiple Myeloma; Newly Diagnosed Multiple Myeloma (NDMM); Newly Diagnosed Multiple Myeloma; Relapsed/Refractory Multiple Myeloma …Oct 2027
Johnson & Johnson (Janssen)Ramantamig
BCMAxGPRC5DxCD3 trispecific antibody
TNFRSF17, CD3E, BCMA, GPRC5DPhase 3Multiple MyelomaDec 2027
Gilead Sciencesanitocabtagene autoleucel
BCMA-directed CAR-T cell therapy
BCMAPhase 3Multiple Myeloma; Muscular DiseasesJul 2028
Dana-Farber Cancer InstituteLinvoseltamab
Bispecific T cell engager targeting CD3 and BCMA
CD3E, BCMAPhase 3Multiple MyelomaOct 2033
Institute of Hematology & Blood Diseases Hospital, ChinaCM336
BCMA/CD3 bispecific antibody
BCMA, CD3EPhase 2Solitary Bone Plasmacytoma; Systemic Light Chain Amyloidosis; POEMS Syndrome; Immune Thrombocytopenia (ITP) …Dec 2026
Institute of Hematology & Blood Diseases Hospital, ChinaEquecabtagene autoleucel
anti-BCMA CAR-T cell therapy
BCMAPhase 2Plasma Cell LeukemiaDec 2026
Institute of Hematology & Blood Diseases Hospital, ChinaYK-BB-002
anti-BCMA CAR-T cell therapy
BCMAPhase 2Plasma Cell LeukemiaDec 2026
Keymed Biosciences Co.LtdCM336
BCMA/CD3 bispecific antibody
BCMA, CD3E, TNFRSF17Phase 2Primary Light-Chain Amyloidosis; Multiple Myeloma; Autoimmune Cytopenia; Autoimmune Bullous DiseaseDec 2026
Institute of Hematology & Blood Diseases Hospital, Chinaanti-BCMA CAR-T
anti-BCMA CAR-T cell therapy
BCMAPhase 2Multiple MyelomaDec 2026
Hrain BiotechnologyHuman BCMA Targeted T Cells Injection (BCMA CAR-T)
BCMA-targeted CAR-T cell therapy
BCMAPhase 2Multiple MyelomaJul 2027
Daihong LiuPD-1Ab21-BCMA CAR-T
BCMA-targeting CAR-T cells secreting PD-1 antibody and interleukin-21 fusion protein
BCMA, PDCD1, IL21Phase 2Multiple MyelomaJul 2027
Institute of Hematology & Blood Diseases Hospital, ChinaBCMA CAR-T
Anti-BCMA CAR-T cell therapy
BCMAPhase 2Multiple Myeloma, Newly Diagnosed; Multiple Myeloma, Plasma Cell LeukemiaAug 2027
Chinese PLA General HospitalAnti-BCMA-CD19 CAR-T cells
Dual-target CAR-T cell therapy targeting CD19 and BCMA antigens
BCMA, CD19Phase 2IgG4 Related DiseaseSep 2027
iCell Gene TherapeuticsICG318
BCMA-CD19 dual-targeting CAR-T cells with IL-15/IL-15 sushi domain
TNFRSF17, CD19, BCMAPhase 2Systemic Lupus Erythematosus (SLE); Inflammatory MyopathyDec 2027
Polina StepenskyHBI0101
anti-BCMA CAR-T cell therapy
BCMAPhase 2Multiple Myeloma, Refractory to Standard Treatment; Systemic Sclerosis (SSc)May 2028
The First Affiliated Hospital of Xiamen UniversityBCMA CAR-T cells
BCMA-targeting CAR-T cell therapy
BCMAPhase 2Multiple MyelomaDec 2028
Institute of Hematology & Blood Diseases Hospital, ChinaQLS4131
BCMA/GPRC5D/CD3 trispecific antibody
BCMA, GPRC5D, CD3Phase 2Primary Plasma Cell LeukemiaDec 2029
Ting Chang, MDCD19-BCMA Targeted CAR-T
Dual CD19-BCMA targeted CAR-T cell therapy
CD19, BCMAPhase 1Myasthenia GravisDec 2026
NexcellaNXC-201 CAR-T
anti-BCMA CAR-T cell therapy
BCMAPhase 1Light Chain (AL) AmyloidosisDec 2026
Lakefront Biotherapeutics WestOM336
Bispecific antibody targeting BCMA and CD3
BCMA, CD3Phase 1AIHA - Warm Autoimmune Hemolytic Anemia; Sjogrens DiseaseDec 2026
Essen BiotechBCMA/CD19 CAR-T cells
chimeric antigen receptor T cells targeting BCMA and/or CD19
BCMA, CD19Phase 1Autoimmune DiseasesDec 2026
Chongqing Precision BiotechBCMA targeted prime CAR-T cells
anti-BCMA CAR-T cell therapy
BCMAPhase 1Multiple MyelomaDec 2026
Nanjing University School of MedicineFKC289
Dual-targeted BCMA/CD19 CAR-T cell therapy
BCMA, CD19Phase 1Lupus NephritisDec 2026
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)MK-4002 (HPN217)
Bispecific antibody targeting BCMA and CD3
BCMA, CD3EPhase 1Multiple Myeloma in RelapseDec 2026
Excyte BiopharmaYKST02
BCMA-CD3 bispecific antibody
BCMA, CD3EPhase 1Relapsed or Refractory Multiple MyelomaDec 2026
The First Affiliated Hospital of Soochow UniversityRN1201 Injection
CD19 and BCMA-targeted allogeneic CAR-T cells
CD19, BCMAPhase 1Multiple Myloma; Refractory Immune-mediated Platelet Transfusion RefractorinessJan 2027
Institute of Hematology & Blood Diseases Hospital, Chinauniversal allogeneic anti-CD19/BCMA CAR T-cells
dual-targeting CAR-T cell therapy targeting CD19 and BCMA
CD19, BCMAPhase 1Autoimmune Hemolytic AnemiaJan 2027
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCD19/BCMA CAR-T cell therapy
Dual-targeted CAR-T cell therapy against CD19 and BCMA
CD19, BCMAPhase 1Systemic Lupus ErythematosusJan 2027
Peter MacCallum Cancer Centre, AustraliaJNJ-68284528 (Cilta-cel)
Anti-BCMA CAR-T cell therapy
BCMAPhase 1Extramedullary MyelomaJan 2027
Gracell Biotechnologies (Shanghai)GC012F
BCMA/CD19 dual CAR-T cell therapy
TNFRSF17, CD19, BCMAPhase 1Multiple Myeloma; Refractory Systemic Lupus Erythematosus; Relapsed/Refractory AL AmyloidosisFeb 2027
Kali TherapeuticsKT501
Monoclonal antibody targeting CD19, BCMA and CD3 to deplete B cells and plasma cells
CD19, BCMA, CD3Phase 1Rheumatoid Arthritis (RA)Feb 2027
Beijing GoBroad Hospitalumbilical cord blood CD19-BCMA CAR-T cells
dual-targeted CAR-T cell therapy targeting CD19 and BCMA
CD19, BCMA, CD5, CD7Phase 1Refractory Lupus Nephritis; T-Cell Non-Hodgkin LymphomaApr 2027
iCell Gene TherapeuticsBCMA-CD19 cCAR T cells
Dual-targeted CAR T cell therapy targeting BCMA and CD19 expressed on B cells and plasma c
BCMA, CD19Phase 1Multiple Myeloma in Relapse; Refractory Immune CytopeniaApr 2027
Beijing GoBroad HospitalDual-targeting BCMA-CD19 CAR-T cell
Dual-target CAR-T cell therapy targeting BCMA and CD19
BCMA, CD19Phase 1Relapsed or Refractory Multiple Myeloma (RRMM)May 2027
Beijing GoBroad HospitalDual-targeting BCMA-GPRC5D CAR-T cell
Dual-target CAR-T cell therapy targeting BCMA and GPRC5D
BCMA, GPRC5DPhase 1Relapsed or Refractory Multiple Myeloma (RRMM)May 2027
The Children's Hospital of Zhejiang University School of Medicineanti-BCMA/CD70 CAR-T cells
CAR-T cell therapy targeting BCMA and CD70
BCMA, CD70Phase 1Multi-Drug Resistant Nephrotic SyndromeJul 2027
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin PharmaceuticalTQB2934
Anti-CD3 × BCMA double-specific antibody (bispecific T-cell engager)
CD3, BCMAPhase 1Multiple MyelomaOct 2027
Xijing HospitalS103 cells
BCMA-directed CAR-T cell therapy
BCMAPhase 1Multiple Sclerosis (MS) Primary ProgressiveNov 2027
Hadassah Medical OrganizationNaive HBI0101 CAR-T
anti-BCMA CAR-T cell therapy
BCMAPhase 1Relapsed/Refractory Multiple Myeloma (MM)Dec 2027
Essen BiotechBCMA/GPRC5D CAR-T cells
Chimeric Antigen Receptor T cells targeting BCMA and/or GPRC5D
BCMA, GPRC5DPhase 1Multiple MyelomaDec 2027
Xuzhou Medical Universityanti-BCMA/FcRL5 CAR-T
dual-targeted CAR-T cell therapy targeting BCMA and FcRL5
BCMA, FCRL5Phase 1Multiple MyelomaDec 2027
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematologyanti-BCMA CAR-T cells
Anti-BCMA CAR-T cell therapy
BCMAPhase 1Multiple Myeloma RefractoryFeb 2028
Institute of Hematology & Blood Diseases Hospital, ChinaUCAR T-cell
universal allogeneic anti-CD19/BCMA CAR T-cells
CD19, BCMAPhase 1Systemic Lupus ErythematosusFeb 2028
Institute of Hematology & Blood Diseases Hospital, ChinaBCMA CART
Anti-BCMA chimeric antigen receptor T-cell therapy
BCMAPhase 1Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm DefinitionsMar 2028
Institute of Hematology & Blood Diseases Hospital, ChinaBCMA-CART
anti-BCMA chimeric antigen receptor T cell therapy
BCMAPhase 1Multiple MyelomaMar 2028
Medical College of WisconsinFT836 CAR T cells
CAR-T cells targeting BCMA (B-cell maturation antigen)
BCMAPhase 1Relapse Multiple MyelomaMar 2028
O&D BioTech GroupO&D-001 injection
Chimeric antigen receptor T cell targeting BCMA and GPRC5D
BCMA, GPRC5DPhase 1Relapsed or Refractory Multiple MyelomaMar 2028
The Children's Hospital of Zhejiang University School of Medicineanti-BCMA/CD70-CAR-T cells
CAR-T cells targeting BCMA and CD70
BCMA, CD70Phase 1CAR T Cell TherapyApr 2028
Ting Chang, MDS103
BCMA-directed CAR-T cell therapy
BCMAPhase 1Myasthenia Gravis, GeneralizedApr 2028
Xi'an No.3 Hospitalallogeneic cord blood-derived, dual-targeting CD19/BCMA CAR-T cells (UCAR-T)
dual-targeting CD19/BCMA CAR-T cell therapy
CD19, BCMAPhase 1Relapsed/Refractory Multiple Myeloma(MM)Jul 2028
Sheba Medical CenterCAR-BCMA
anti-BCMA CAR-T cell therapy
BCMAPhase 1Multiple MyelomaSep 2028
Chongqing Precision BiotechBCMA/CD70-targeted CAR-T
Dual-targeted CAR-T cell therapy against BCMA and CD70
BCMA, CD70Phase 1Juvenile Dermatomyositis (JDM)Sep 2028
National Institute of Allergy and Infectious Diseases (NIAID)CART-BCMA
Chimeric Antigen Receptor T cell targeting B cell maturation antigen
BCMAPhase 1Kidney TransplantDec 2028
Chinese PLA General HospitalKSVCBD injection
in vivo CAR-T therapy targeting CD19 and BCMA
CD19, BCMAPhase 1Multiple Myeloma; Non-Hodgkin's LymphomaDec 2028
The Children's Hospital of Zhejiang University School of MedicineUCAR T-cell
Universal allogeneic anti-CD19/BCMA CAR T-cells
CD19, BCMAPhase 1Autoimmune DiseasesDec 2028
Institute of Hematology & Blood Diseases Hospital, ChinaQT-019C
universal allogeneic anti-CD19/BCMA CAR T-cells
CD19, BCMAPhase 1SLE - Systemic Lupus ErythematosusJan 2029
Shanghai Chia Tai Tianqing Pharmaceutical Technology DevelopmentTQB2934 injection
Bispecific antibody targeting BCMA and CD3
BCMA, CD3EPhase 1Systemic Light Chain AmyloidosisFeb 2029
Poseida TherapeuticsP-BCMA-ALLO1
allogeneic BCMA-targeted CAR-T cell therapy
BCMAPhase 1Multiple MyelomaMar 2029
University College, LondonBCMA CAR T cells
CAR T cells targeting BCMA
BCMAPhase 1Multiple MyelomaMar 2029
University College, LondonBCMA/CD19 CAR T cells
CAR T cells co-expressing BCMA and CD19 CARs
BCMA, CD19Phase 1Multiple MyelomaMar 2029
Columbia University131I-apamistamab
Anti-BCMA radioimmunconjugate (iodine-131 labeled monoclonal antibody)
BCMAPhase 1Sickling Disorder Due to Hemoglobin SMar 2030
Celyad OncologyCYAD-211
Allogeneic anti-BCMA chimeric antigen receptor (CAR) T-cell
BCMAPhase 1Relapse/Refractory Multiple MyelomaFeb 2037
Shanghai AbelZetaC-CAR088
BCMA-directed CAR-T cell therapy
BCMAPhase 1Multiple MyelomaJul 2037
Thomas Martin, MDManufactured Anti-BCMA CAR-T cells
anti-BCMA chimeric antigen receptor T cell therapy
BCMAPhase 1Refractory Multiple MyelomaAug 2038
Dispatch BiotherapeuticsDISP-10
Combination therapy consisting of DV-10 (adenovirus) and idecabtagene vicleucel (BCMA-dire
BCMAPhase 1Colorectal CancerApr 2046
Institute of Hematology & Blood Diseases Hospital, ChinaC-CAR088
anti-BCMA CAR-T cell
BCMAPhase 1Multiple Myeloma–
AbbVieTNB-383B
BCMA x CD3 T-cell engaging bispecific antibody
BCMA, CD3EPhase 1Multiple Myeloma–

Conditions

Multiple Myeloma (50) Relapsed/Refractory Multiple Myeloma (4) Plasma Cell Leukemia (4) Systemic Light Chain Amyloidosis (2) Relapsed Refractory Multiple Myeloma (RRMM) (2) Multiple Myeloma, Newly Diagnosed (2) Systemic Lupus Erythematosus (2) Relapsed or Refractory Multiple Myeloma (RRMM) (2) Multiple Myeloma in Relapse (2) Relapsed or Refractory Multiple Myeloma (2) Autoimmune Diseases (2) Refractory Lupus Nephritis (2)

Modalities

other (35), mixed (14), small molecule (9), protein or peptide (8), antibody (5)

Companies

Institute of Hematology & Blood Diseases Hospital, China (12) Beijing GoBroad Hospital (3) The Children's Hospital of Zhejiang University School of Medicine (3) Ting Chang, MD (2) Chinese PLA General Hospital (2) iCell Gene Therapeutics (2) Essen Biotech (2) AbbVie (2) University College, London (2) Chongqing Precision Biotech (2) Poseida Therapeutics (1) Sheba Medical Center (1) Regeneron Pharmaceuticals (1) Johnson & Johnson (Janssen) (1) Xijing Hospital (1) AstraZeneca (1) Lakefront Biotherapeutics West (1) Nanjing University School of Medicine (1) Polina Stepensky (1) Gracell Biotechnologies (Shanghai) (1)

Related targets

CD19 (20) CD3E (10) GPRC5D (6) TNFRSF17 (5) CD3 (4) CD70 (3) PDCD1 (1) IL21 (1) CD5 (1) CD7 (1) FCRL5 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.